Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004206945 | SCV003708343 | uncertain significance | not specified | 2024-01-03 | criteria provided, single submitter | clinical testing | The c.928G>A (p.E310K) alteration is located in exon 4 (coding exon 4) of the DACT1 gene. This alteration results from a G to A substitution at nucleotide position 928, causing the glutamic acid (E) at amino acid position 310 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV004598253 | SCV005093193 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | DACT1: BP4, BS1 |
Prevention |
RCV003928925 | SCV004742144 | benign | DACT1-related disorder | 2019-05-11 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |